With Democrats now poised to gain control of both chambers of Congress, AMCP published the following deck to outline the impacts of the 2026 midterm election on federal health policy.
On Aug. 6, AMCP responded to FDA’s draft guidance on considerations in demonstrating biosimilar interchangeability with a biologic reference product. The draft guidance, issued on June 17, describes considerations regarding switching studies which demonstrate interchangeability between biosimilars and their reference biologic products.
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.